|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 9 (May 1), 1997:
pp. 3490-3490
CORRESPONDENCE
Cytotoxic T-Lymphocyte Differentiation and Cytogenetic Alterations in   Hepatosplenic T-Cell Lymphoma and Posttransplant Lymphoproliferative Disorders
 |
LETTER |
To the Editor:
We read with great interest the recent reports on hepatosplenic   T-cell lymphoma ( HSTCL)1 and T-cell posttransplant lymphoproliferative disorders (T-PTLD).2 Since 1991 we have encountered 5 patients with HSTCL: 2 occurred in chronic renal transplant patients (Salhany et al, unpublished data, November 1996), but the other 3 patients were not immunosuppressed.3 Our cases were clonal CD4-, CD8- T-cell lymphomas with hepatosplenic involvement, which expressed T-cell receptors (TCR) and natural killer (NK) cell-associated antigens (4/5 CD16+ and CD56+, 1/5 CD11c+). Most presented with fever, anemia, and thrombocytopenia, but 2 also presented with severe neutropenia.3 Three of 5 patients died within 5 to 10 months of progressive lymphoma with only minimal response to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy; 2 terminally developed overt leukemia. However, one nontransplant patient had a complete response to CHOP, but died of aplastic anemia 22 months later with no evidence of lymphoma at autopsy.3
We were gratified to see that Cooke et al1 have confirmed our previous observation that HSTCL are derived from cytotoxic T lymphocytes (CTL).4 We have subsequently demonstrated CTL differentiation in 4 additional HSTCL3 (and unpublished data, November 1996). All cases expressed cytolytic effector and cytolytic granule-associated proteins, including Fas ligand (5/5), TIA-1 (5/5), perforin (3/5), and granzyme B (3/5). Moreover, we have recently demonstrated TCR-mediated cytolytic activity and antibody-dependent cellular cytotoxicity (ADCC) in a CD16+, CD56+ HSTCL.3 Cooke et al1 suggested that HSTCL represent NK-like T cells based on frequent coexpression of the NK cell-associated antigens CD16 and CD56; however, we did not find NK-like, non-major histocompatibility complex restricted, spontaneous cytolysis of K562 cells in one CD16+, CD56+ HSTCL studied thus far (Salhany and Peritt, unpublished data, November 1996). Interestingly, however, we did demonstrate interferon- (IFN-) production by one HSTCL in a patient presenting with severe neutropenia.3 IFN--induced suppression of granulocytopoiesis has been implicated in the pathogenesis of severe neutropenia in a patient with subcutaneous T-cell lymphoma,5 suggesting a similar mechanism in our case.
Isochromosome 7q has been espoused by Cooke et al and others as a cytogenetic abnormality that may define HSTCL as a distinct entity.1,6 However, we found i(7q) in only 1 of 4 HSTCL studied by standard cytogenetics (Salhany and Nowell, unpublished data, November 1996).3 Our cytogenetic studies and those of others7,8 suggest that i(7q) is not a consistent cytogenetic abnormality in HSTCL. Moreover, i(7q) is not specific for HSTCL; i(7q) has also been reported in acute myeloid leukemia, acute lymphoblastic leukemia, prolymphocytic leukemia, and Wilms' tumor.3,9 Interestingly, trisomy 8 has accompanied i(7q) in 5 of 7 reported cases, including our case and one from Cooke et al.1,3,6
We agree that HSTCL is a distinct clinicopathologic entity, but have noted more morphologic, immunophenotypic, cytogenetic, and clinical heterogeneity than observed by Cooke et al.1 Moreover, we have shown that HSTCL can be derived from different T-cell subsets; 4 of 5 were derived from V1 T-cells, whereas the other was derived from neither V1 nor V2 subsets3 (and unpublished data). Gaulard et al have reported similar findings.10 Interestingly, our V1- HSTCL was different from the V1+ cases, including presence of a small cell component, negative CD16 and CD56, lack of i(7q), severe neutropenia, massive hemophagocytosis, IFN- secretion without cytolytic activity, and complete response to CHOP chemotherapy.3
Our 2 posttransplant HSTCL cases share similarities to the 6 T-PTLD cases described by Hanson et al,2 except for CD8 expression by their cases. CD8 is more commonly expressed by   T cells, but CD8 can be expressed by some HSTCL,1 suggesting possible T-cell origin for Hanson's T-PTLD cases.2 Unfortunately, they did not evaluate their T-PTLD for or TCR expression,2 but retrospective study with F1 might allow direct or indirect determination of the TCR subtypes. Regardless of or TCR subtype, expression of CD16 or CD56 and ultrastructural demonstration of type I cytolytic granules11 support CTL origin of their T-PTLD2; this could be confirmed by immunohistochemical staining for TIA-1, perforin or granzyme B.1,3 Interestingly, both of our T-PTLD and all 6 of their T-PTLD2 developed in chronic renal transplant patients, suggesting that chronic CTL proliferation may be important in the pathogenesis of T-PTLD. Neither of our T-PTLD patients responded to reduction in immunosuppression, but both had partial responses to chemotherapy; however, the response in one patient was short-lived, terminating in overt leukemia and death within 6 months. Follow-up in the other patient is only 1 month. Hanson et al2 reported similar responses. Thus, it appears that, unlike B-PTLD, T-PTLD does not respond to reduction in immunosuppression alone, and should be treated with chemotherapy at diagnosis.
Kevin E. Salhany
Michael Feldman
David Peritt
Peter C. Nowell
Department of Pathology and Laboratory Medicine Division of Anatomic Pathology University of Pennsylvania School of Medicine and Wistar Institute Philadelphia, PA
| |
ACKNOWLEDGMENT |
Supported in part by a McCabe Fund Award (K.E.S.).
| |
REFERENCES |
1.
Cooke CB,
Krenacs L,
Stetler-Stevenson M,
Greiner TC,
Raffeld M,
Kingma DW,
Abruzzo L,
Frantz C,
Kaviani M,
Jaffe ES:
Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic T-cell origin.
Blood
88:4265,
1996[Abstract/Free Full Text]
2.
Hanson MN,
Morrison VA,
Peterson BA,
Steiglbauer KT,
Kubic VL,
McCormick SR,
McGlennen RC,
Manivel JC,
Brunning RD,
Litz CE:
Posttransplant T-cell lymphoproliferative disorders: An aggressive, late complication of solid-organ transplantation.
Blood
88:3626,
1996[Abstract/Free Full Text]
3. Salhany KE, Feldman M, Kahn MJ, Peritt D, Schretzenmair RD, Wilson DM, DiPaola RS, Glick AD, Kant JA, Nowell PC, Kamoun M: Hepatosplenic T cell lymphoma: Ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte (CTL) differentiation. Hum Pathol (in press)
4. Salhany K, Kahn M, Kamoun M, Kant J, Glick A, Loh E: Hepatosplenic T cell lymphoma: An aggressive cytolytic peripheral T-cell lymphoma presenting with severe neutropenia. Mod Pathol 7:119A, 1994 (abstr)
5.
Wilhelm M,
Meyer P,
Batram C,
Tony HP,
Dummer R,
Nestle F,
Burg G,
Wilms K:
/ Receptor-expressing T-cell clones from a cutaneous T-cell lymphoma suppress hematopoiesis.
Ann Hematol
65:111,
1992[Medline]
[Order article via Infotrieve]
6.
Wang CC,
Tien HF,
Lin MT,
Su IJ,
Wang CH,
Chuang SM,
Shen MC,
Liu CH:
Consistent presence of isochromosome 7q in hepatosplenic T / lymphoma: A new cytogenetic-clinicopathologic entity.
Genes Chromosom Cancer
12:161,
1995[Medline]
[Order article via Infotrieve]
7.
Ross CW,
Schnitzer B,
Sheldon S,
Braun DK,
Hanson CA:
Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen.
Am J Clin Pathol
102:310,
1994[Medline]
[Order article via Infotrieve]
8.
Wong KF,
Chan JKC,
Matutes E,
McCarthy K,
Ng CS,
Chan CH,
Ma SK:
Hepatosplenic T-cell lymphoma: A distinctive aggressive lymphoma type.
Am J Surg Pathol
19:718,
1995[Medline]
[Order article via Infotrieve]
9.
Labal de Vinuesa M,
Slavutsky I,
Larripa I:
Presence of isochromosomes in hematologic diseases.
Cancer Genet Cytogenet
25:47,
1987[Medline]
[Order article via Infotrieve]
10.
Gaulard P,
Bourquelot P,
Kanavaros P,
Haioun C,
Le Couedic JP,
Divine M,
Goossens M,
Zafrani ES,
Farcet JP,
Reyes F:
Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas: Identification of a subset of / T-cell lymphomas.
Am J Pathol
137:617,
1990[Abstract]
11.
Griffiths GM,
Argon Y:
Structure and biogenesis of lytic granules.
Curr Top Microbiol Immunol
198:39,
1995[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Belhadj, F. Reyes, J.-P. Farcet, H. Tilly, C. Bastard, R. Angonin, E. Deconinck, F. Charlotte, V. Leblond, E. Labouyrie, et al.
Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients
Blood,
December 15, 2003;
102(13):
4261 - 4269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Aljurf, T. W. Owaidah, A. Ezzat, E. Ibrahim, and A. Tbakhi
Antigen- and/or immune-driven lymphoproliferative disorders
Ann. Onc.,
November 1, 2003;
14(11):
1595 - 1606.
[Full Text]
[PDF]
|
|
|
| |
